Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bartl

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Der Unfallchirurg|April 15, 2005
[Osteoporosis in traumatology. Prevalence and management]T Vogel, T Dobler, H Bitterling, et al.
Scandinavian Journal of Haematology|October 1, 1983
Bone marrow histology in Waldenström's macroglobulinaemia. Clinical relevance of subtype recognitionR Bartl, B Frisch, G Mahl, et al.
Leukemia & Lymphoma|June 30, 2004
Genetic analyses permit the differentiation between reactive malfunctions ('promyelocyte arrest') and arising promyelocyte leukemia in a pregnant patient with a history of a medulloblastomaBrigitte Poleck-Dehlin, T Duell, R Bartl, et al.
Annals of Hematology|March 1, 1992
Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cellsR Leo, M Boeker, D Peest, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|July 16, 2005
[Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma]K Wasser, T Moehler, S Nosas-Garcia, et al.
British Journal of Haematology|February 1, 1995
Low-dose recombinant interleukin-2 therapy in advanced multiple myelomaD Peest, R Leo, S Bloche, et al.
Der Internist|September 17, 2009
[Reduced bone density and bone pain :osteomalacia with hypophospatemia and hypophosphaturia]H M Findeisen, C J Auernhammer, K G Parhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment GroupD Peest, H Deicher, R Coldewey, et al.
Annals of Hematology|January 1, 1994
Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversalV Nüssler, R Pelka-Fleischer, H Zwierzina, et al.
Onkologie|December 1, 1990
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment GroupD Peest, H Deicher, R Coldewey, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Der Unfallchirurg|April 15, 2005
[Osteoporosis in traumatology. Prevalence and management]T Vogel, T Dobler, H Bitterling, et al.
Scandinavian Journal of Haematology|October 1, 1983
Bone marrow histology in Waldenström's macroglobulinaemia. Clinical relevance of subtype recognitionR Bartl, B Frisch, G Mahl, et al.
Leukemia & Lymphoma|June 30, 2004
Genetic analyses permit the differentiation between reactive malfunctions ('promyelocyte arrest') and arising promyelocyte leukemia in a pregnant patient with a history of a medulloblastomaBrigitte Poleck-Dehlin, T Duell, R Bartl, et al.
Annals of Hematology|March 1, 1992
Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cellsR Leo, M Boeker, D Peest, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|July 16, 2005
[Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma]K Wasser, T Moehler, S Nosas-Garcia, et al.
British Journal of Haematology|February 1, 1995
Low-dose recombinant interleukin-2 therapy in advanced multiple myelomaD Peest, R Leo, S Bloche, et al.
Der Internist|September 17, 2009
[Reduced bone density and bone pain :osteomalacia with hypophospatemia and hypophosphaturia]H M Findeisen, C J Auernhammer, K G Parhofer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment GroupD Peest, H Deicher, R Coldewey, et al.
Annals of Hematology|January 1, 1994
Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversalV Nüssler, R Pelka-Fleischer, H Zwierzina, et al.
Onkologie|December 1, 1990
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment GroupD Peest, H Deicher, R Coldewey, et al.
Pageof 13